Cencora (COR) – Investment Analysts’ Weekly Ratings Changes

Cencora (NYSE: COR) recently received a number of ratings updates from brokerages and research firms:

  • 11/18/2026 – Cencora had its price target raised by Barclays from $350.00 to $415.00. They now have an “overweight” rating on the stock.
  • 11/17/2026 – Cencora had its price target raised by Wells Fargo & Company from $395.00 to $400.00. They now have an “overweight” rating on the stock.
  • 11/10/2026 – Cencora had its price target raised by JPMorgan Chase & Co. from $390.00 to $413.00. They now have an “overweight” rating on the stock.
  • 11/5/2026 – Cencora had its price target raised by Leerink Partners from $388.00 to $405.00. They now have an “outperform” rating on the stock.
  • 10/30/2026 – Cencora had its price target raised by Morgan Stanley from $346.00 to $377.00. They now have an “overweight” rating on the stock.
  • 10/22/2026 – Cencora had its price target raised by Robert W. Baird from $373.00 to $375.00. They now have an “outperform” rating on the stock.
  • 10/20/2026 – Cencora had its price target raised by Argus from $340.00 to $380.00. They now have a “buy” rating on the stock.
  • 10/16/2026 – Cencora had its price target lowered by UBS Group from $430.00 to $400.00. They now have a “buy” rating on the stock.
  • 10/12/2026 – Cencora had its price target raised by Robert W. Baird from $370.00 to $373.00. They now have an “outperform” rating on the stock.
  • 10/7/2026 – Cencora had its price target raised by Leerink Partners from $380.00 to $388.00. They now have an “outperform” rating on the stock.
  • 10/6/2026 – Cencora was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.

Cencora Price Performance

Shares of Cencora stock traded down $7.26 during trading on Thursday, hitting $341.05. 1,408,720 shares of the stock traded hands, compared to its average volume of 1,466,187. The company has a quick ratio of 0.59, a current ratio of 0.94 and a debt-to-equity ratio of 3.01. The stock has a market cap of $65.08 billion, a price-to-earnings ratio of 19.03, a PEG ratio of 1.81 and a beta of 0.58. The firm’s fifty day moving average is $328.67 and its 200-day moving average is $317.17. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54.

Cencora (NYSE:COR – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.08. The company had revenue of $88.35 billion for the quarter, compared to analysts’ expectations of $87.95 billion. Cencora had a return on equity of 110.72% and a net margin of 1.03%. Cencora’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the firm posted $3.84 EPS. Research analysts expect that Cencora, Inc. will post 19.58 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be paid a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 0.8%. This is a boost from Cencora’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, November 13th. Cencora’s payout ratio is 14.73%.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the company’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This represents a 36.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.38% of the company’s stock.

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Read More

Receive News & Ratings for Cencora Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora Inc and related companies with MarketBeat.com's FREE daily email newsletter.